Compare MDBH & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | VERU |
|---|---|---|
| Founded | 1997 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 39.8M |
| IPO Year | 2023 | 1990 |
| Metric | MDBH | VERU |
|---|---|---|
| Price | $3.65 | $2.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 11.0K | ★ 122.9K |
| Earning Date | 11-13-2025 | 12-16-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | $1,250,398.00 | ★ $16,886,419.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.63 | ★ N/A |
| Revenue Growth | N/A | ★ 337.24 |
| 52 Week Low | $3.16 | $2.11 |
| 52 Week High | $7.98 | $14.20 |
| Indicator | MDBH | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 39.28 |
| Support Level | $3.30 | $2.33 |
| Resistance Level | $3.69 | $2.51 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 27.12 | 58.68 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.